Compare Ralph Lauren Corp (RL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs TG Therapeutics Inc — how do they compare? Ralph Lauren Corp trades at $387.44 (market cap $22.79B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Ralph Lauren Corp is far larger — about 2.8× TG Therapeutics Inc's market cap, and Ralph Lauren Corp pays a 0.98% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RL | TGTX | |
|---|---|---|
Market Cap | $22.79B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $59.06 |
52-Week Low | $283.34 | $26.39 |
Enterprise Value | $23.73B | $8.50B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $382.93, up 0.65% today, with strong fundamentals including 11.6% net margin and 34.66% ROE. Recent earnings beats and a $1.00 dividend signal financial health, though technical indicators show bearish momentum near resistance at $383. Revenue growth to $7.08B in 2025 and a $445.71 analyst target suggest upside potential.
The stock offers growth through premium branding and digital expansion, but faces risks from consumer discretionary weakness and high valuation multiples. Analyst consensus is strongly bullish (66% buy ratings), yet technical pressure and macroeconomic sensitivity warrant caution for near-term entry points.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
